January 5, 2017
Neovacs and Professor Robert Kerbel together fight cancer
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 4, 2017
Bayer nets FDA’s priority review for cancer drug in U.S.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
January 4, 2017
Sanofi’s type 2 diabetes drug available in U.S.
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
January 4, 2017
J&J’s DePuy Synthes acquires Interventional Spine expandable cage technology
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
January 4, 2017
Eli Lilly’s subsidiary Elanco buys BIVI
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…
January 4, 2017
FDA said ok to Allergen’s breast implants
Allergan has won FDA’s approval to sell its breast implants in US.
January 4, 2017
Sanofi enters New Year with new deal, ends its vaccine joint venture
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
January 4, 2017
Gilead reinforces oncology department from Novartis
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
January 3, 2017
Shire enters new year with new non-executive director
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
December 30, 2016
Mylan launches three different tablets in US in two days
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.